Henry Skinner is the CEO of the AMR Action Fund, leveraging a deep background as a microbiologist, venture investor, and pharmaceutical executive to address antimicrobial resistance. His career includes leadership roles at Tekla Capital Management and Novartis Venture Fund, alongside CEO positions at biotech firms. He holds a PhD in Microbiology and an MS in Bioethics from Harvard.
Henry has a long-standing personal interest in microbiology and the history of medicine, which began during his undergraduate studies. This passion has driven his 25-year career in biotech and pharma, where he has consistently focused on developing novel antibiotics and tackling infectious diseases.
He once ran a company that focused on discovering new antibiotics by isolating them from the environment.
Read the full overview →Behavioral traits and communication patterns that shape how this person evaluates opportunities, builds trust, and makes decisions in professional settings.
Dominance, influence, steadiness, and calculativeness scores with guidance on how this person prefers to communicate and decide.
Discover additional public profiles from our index.
Looking for someone else? Search here for anyone.